Michael Holinstat, Ph.D., FAHA

“Oxylipin pathways in the platelet reveal new targets for prevention and treatement of cardiovascular diseases”

Dr. Michael Holinstat is a professor in the department of pharmacology and a fellow of the American Heart Association. His research interests focus on understanding lipid, lipoxygenase, and oxygenase regulation of platelet signaling and function and how it relates to regulation of hemostasis and thrombosis. He serves as the inaugural Director of the Platelet Physiology and Pharmacology Platelet Core at the University of Michigan, and on several national boards including the sub-committee on Hemostasis and Thrombosis at the American Society for Hematology and the Director for the NIH CTSI-funded T32 training grant in clinical research.

Dr. Holinstat has received several national awards including the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from the Council on Arteriosclerosis, Thrombosis, and Vascular Biology in 2012 and the Young Investigator Award in Structure-Function from the Eicosanoid Research Foundation in 2013. He has received numerous patents in the US, EU, and Japan for various therapeutic discoveries to treat cardiovascular disease and has been continuously funded since 2005. You will find Dr. Holinstat has also developed a number of first-in-class antiplatelet drugs including the 12-lipoxygenase inhibitor (ML355) and prostacyclin receptor agonist (CS585) that are both in various stages of clinical development for thrombosis. He published over 102 peer-reviewed publications in the area of platelet biology and lipids and has spent the last 20 years training the next generation of clinical and translational scientists in the area of blood clotting and platelet biochemistry including undergraduates, graduate students, postdoctoral fellows, clinical fellows, and basic and clinical faculty.